For the Inventor, By the Inventor

Enter inventor name

Fremont, CA, United States of America

Sarah Lee Pogue

USPTO Granted Patents = 18 (Patent Applications = 2)

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 3)

Average Co-Inventor Count = 5.5

ph-index = 6

Forward Citations = 114(Granted Patents)

Location History:

Frazer, PA (US) (2017 - 2019)
Fremont, CA (US) (2009 - 2021)
Freemont, CA (US) (2017 - 2021)
North Wales, PA (US) (2022)
Redwood City, CA (US) (2018 - 2023)

Company Filing History:

Teva Pharmaceuticals Australia Pty Ltd

Bristol-myers Squibb Compnay

4. 1 out of 575

Ono Pharmaceutical Co., Ltd.

Teva Pharmaceuticals Pty Ltd

Oxford Biotherapeutics Ltd

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Loading Chart...

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258401 - Anti-CD47 combination therapy (2025-03-25),

2. 11618784 - Anti-CD47 combination therapy (2023-04-04),

3. 11253591 - Combination of lenalidomide and polypeptide construct, and uses thereof (2022-02-22),

4. 11117975 - Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B (2021-09-14),

5. 10981986 - Fusions of antibodies to CD38 and attenuated interferon alpha (2021-04-20),

6. 10232041 - Combination of lenalidomide and polypeptide construct, and uses thereof (2019-03-19),

7. 9963515 - Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B (2018-05-08),

8. 9932411 - Antibodies (2018-04-03),

9. 9636334 - Combination of lenalidomide and polypeptide construct, and uses thereof (2017-05-02),

10. 9611322 - Fusions of antibodies to CD38 and attenuated interferon alpha (2017-04-04),

11. 8758757 - Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) (2014-06-24),

12. 8496931 - Monoclonal antibodies against stromal derived factor-1 (SDF-1) (2013-07-30),

13. 8425904 - Human antibodies that bind mesothelin, and uses thereof (2013-04-23),

14. 8399623 - Human antibodies that bind mesothelin, and uses thereof (2013-03-19),

15. 8383779 - Human antibodies that bind mesothelin, and uses thereof (2013-02-26),

Title: Biography of Sarah Lee Pogue

Introduction

Sarah Lee Pogue is an accomplished inventor based in Fremont, CA (US). She has made significant contributions to the field of medical therapies, particularly in cancer treatment. With a total of 18 patents to her name, Pogue has established herself as a leading innovator in her area of expertise.

Latest Patents

One of her latest patents is focused on Anti-CD47 combination therapy. This invention provides a combination therapy for treating tumors in subjects. The combination comprises two elements. The first is a polypeptide construct that includes an attenuated Type I interferon (IFN) linked to an antibody, which binds to a cell surface-associated antigen expressed on the tumor cell and includes a functional Fc region. The second element is a CD47 antagonist that inhibits the interaction between CD47 and the SIRPα receptor.

Career Highlights

Throughout her career, Pogue has worked with notable companies in the pharmaceutical industry. She has been associated with Teva Pharmaceuticals Australia Pty Ltd and Bristol-Myers Squibb Company, where she has contributed her expertise in developing innovative therapies.

Collaborations

Pogue has collaborated with esteemed professionals in her field, including Anthony Gerard Doyle and Tetsuya Taura. These collaborations have further enhanced her research and development efforts in medical innovations.

Conclusion

Sarah Lee Pogue continues to be a

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…